about
Structure and inhibition of human diamine oxidaseThe in vitro efficacy of antimicrobial agents against the pathogenic free-living amoeba Balamuthia mandrillarisHigh prevalence of drug resistance in animal trypanosomes without a history of drug exposureTrypanosoma evansi and surra: a review and perspectives on transmission, epidemiology and control, impact, and zoonotic aspectsAngiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in miceIn vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sicknessAngiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysmsShort-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 activity in rats with subtotal nephrectomy.High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke.ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease TherapyCurrent advances in detection and treatment of babesiosisHuman African trypanosomiasis: pharmacological re-engagement with a neglected disease.Bovine trypanosomiasis in south-western Uganda: packed-cell volumes and prevalences of infection in the cattle.Trypanocidal action of Lippia alba and Lippia origanoides essential oils against Trypanosoma evansi in vitro and in vivo used mice as experimental model.The animal trypanosomiases and their chemotherapy: a reviewThe vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.Serum biochemical parameters and cytokine profiles associated with natural African trypanosome infections in cattle.Glycosaminoglycans are potential pharmacological targets for classic DNA minor groove binder drugs berenil and pentamidine.Effects of treatment with the anti-parasitic drug diminazene aceturate on antioxidant enzymes in rat liver and kidney.Curative drug treatment of trypanosomosis leads to the restoration of B-cell lymphopoiesis and splenic B-cell compartments.Diminazene enhances stability of atherosclerotic plaques in ApoE-deficient mice.Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes.Cordycepin (3'-deoxyadenosine) pentostatin (deoxycoformycin) combination treatment of mice experimentally infected with Trypanosoma evansi.Degradation of berenil (diminazene aceturate) in acidic aqueous solution.Indole and Benzimidazole Bichalcophenes: Synthesis, DNA Binding and Antiparasitic Activity.Unveiling the effects of berenil, a DNA-binding drug, on Trypanosoma cruzi: implications for kDNA ultrastructure and replication.Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): Trypanosoma evansi infections (including Surra)Fumagillin, a new P-glycoprotein-interfering agent able to modulate moxidectin efflux in rat hepatocytes.Failure of efficacy and adverse events associated with dose-intense diminazene diaceturate treatment of chronic Cytauxzoon felis infection in five cats.Trypanocidal Effects of Cisplatin alone and in Combination with Nigella sativa Oil on Experimentally Infected Mice with Trypanosoma evansi.The small molecule drug diminazene aceturate inhibits liver injury and biliary fibrosis in mice
P2860
Q24317424-0FA0A575-DAB7-484B-B6CF-B7CAF0799E2DQ28294820-A750E624-89CF-49C8-ADCE-AC58E99A06D9Q28478493-C412C69B-3AF8-479E-B9DD-62F4375262A4Q28677323-D257D0A9-7448-4520-B598-6AF34D87C431Q33773490-A778DD22-E94B-4EF5-9E91-DFB764156CEBQ34058294-664BA32F-D098-437D-848F-0B52BDB5F5A2Q34606642-CAF819B9-94A8-410D-948D-F342A75379BFQ35192530-423BD097-7258-4CA5-84EC-A545DA3635D1Q35353325-9C98344D-AEF6-409F-88E1-B64F3286BE1AQ35534662-CAFE76C2-E638-4DEB-B044-551073E9830FQ35760437-B24A56BF-23AF-4DEF-A0C3-EB65FEF715D9Q35969816-F0B7A0A7-25D8-47A4-AF03-2F81D2BAC30EQ36740553-BB4BF324-F7C1-468F-AE0B-2DBD49F5B7BCQ38882348-BDDA47F8-3924-4742-9D94-04500C39087CQ38889915-E251B7A6-E6F2-4ADA-88A2-83ADF6723E0AQ38975883-D5EEB68C-8EAB-4FDE-86BD-E363827DCB09Q39376362-D2E7BD8A-3902-488C-87B3-A5CC0C149265Q40156101-09B57A52-09A0-45EE-BABE-1185A3AE86E1Q40568383-BF6A2814-4BD8-4BCD-9B3C-F45B3768FEACQ40818655-8CFC7495-2EC4-4767-9946-2898EF4ED806Q41162094-AB116EF7-58B0-45F2-AE17-E3A98B542108Q41572699-48708CC6-5E6F-45F2-9222-F69782FF2B7EQ42432966-1AEB4FE3-BA46-4A24-B960-0008BBC861B4Q44791311-80F1AA94-68FA-40CC-9468-128B9EA62FE1Q45105477-BAEC3263-4705-4A5C-BB64-486BE7A1BF38Q46444190-28C84592-2C7F-492B-A7D2-32AF7A438AF2Q46821071-B3105FD0-52B2-4CEB-AB34-C8F2C78A7EA3Q47159923-E94727D3-CBB8-43CD-AC6C-49334373EB59Q52673902-2E2B43FE-9419-48C3-8C0A-6BD95002EA2FQ54243039-FA755AF6-E8F6-439A-912C-6622883FC3BFQ55364772-A59279D0-610E-43BB-97E6-6D0D78DF639BQ57115264-ED392C50-D566-464E-AEFC-488849E619E2
P2860
description
1993 nî lūn-bûn
@nan
1993 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Pharmacology of diminazene: a review.
@ast
Pharmacology of diminazene: a review.
@en
Pharmacology of diminazene: a review.
@nl
type
label
Pharmacology of diminazene: a review.
@ast
Pharmacology of diminazene: a review.
@en
Pharmacology of diminazene: a review.
@nl
prefLabel
Pharmacology of diminazene: a review.
@ast
Pharmacology of diminazene: a review.
@en
Pharmacology of diminazene: a review.
@nl
P921
P1433
P1476
Pharmacology of diminazene: a review.
@en
P2093
Peregrine AS
P304
P356
10.1016/0001-706X(93)90092-P
P577
1993-09-01T00:00:00Z